FDA Announces Guidance to Reduce Demand for Nonhuman Primates in Pharmaceutical Studies Due to Reduced Supply of Animals During the COVID-19 Pandemic

The Food & Drug Administration (FDA) has announced the availability of a final guidance for “Nonclinical Considerations for Mitigating Nonhuman Primate Supply Constraints Arising from the COVID-19 Pandemic” due to a significant reduction in the supply of nonhuman primates available for conducting toxicology studies for new pharmaceuticals. The guidance, which provides FDA recommendations to reduce the demand for nonhuman primates, is being implemented without a formal public comment period.